[Case of ulcerative colitis refractory to intravenous cyclosporine therapy successfully treated with infliximab].
A 26-year-old woman was admitted to our hospital with relapse of ulcerative colitis (UC). We diagnosed it as a refractory UC because intravenous corticosteroid therapy had no effect. Intravenous cyclosporine therapy and other conventional therapies did not lead to remission. Then the possibility of infliximab was discussed with the patient and her parents and treatment with infliximab was started. Infliximab was infused intravenously at a dose of 5mg per kilograms of body weight. Immediately after the first infusion, clinical symptoms improved, and clinical remission was achieved within 12 weeks. It is suggested that infliximab can be effective for refractory UC.
Tsuya
Ryosuke
R
Division of Gastroenterology, Sapporo Kosei General Hospital.
Motoya
Satoshi
S
Tanaka
Hiroki
H
Nakagaki
Suguru
S
Nishioka
Hitoshi
H
Hagiwara
Takeshi
T
Kozawa
Hiroshi
H
Kurokawa
Sei
S
Ambo
Tomonori
T
Imamura
Akimichi
A
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D016572:Cyclosporine / Q000008:administration & dosage; D004334:Drug Administration Schedule; D004351:Drug Resistance; D005260:Female; D005765:Gastrointestinal Agents / Q000008:administration & dosage*; D006801:Humans; D000069285:Infliximab; D007262:Infusions, Intravenous; D011239:Prednisolone / Q000008:administration & dosage; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D016572:Cyclosporine; D011239:Prednisolone; D000069285:Infliximab